Headlines
Novo Nordisk's head of commercial strategy steps down
Published by Global Banking & Finance Review®
Posted on April 3, 2025
2 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 3, 2025
2 min readLast updated: January 24, 2026
Camilla Sylvest steps down from Novo Nordisk, with Ludovic Helfgott taking over her role. The company remains committed to DEI initiatives.
By Maggie Fick and Stine Jacobsen
LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.
Novo's rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said.
Sylvest was one of two women on Novo's 10-person executive management team. Well known to investors and analysts, she was a consistent presence alongside Chief Executive Officer Lars Fruergaard Jorgensen, Chief Financial Officer Karsten Munk Knudsen, and others on earnings calls.
Novo's statement on Thursday said that Sylvest had decided to leave and did not cite a reason.
Another woman, Thilde Hummel Bøgebjerg, was promoted to the executive management team on Thursday, as executive vice president for Quality, IT & Environmental Affairs.
While some European pharmaceutical companies - including Swiss drugmakers Roche and Novartis - have abandoned global diverse workforce targets in response to recent U.S. executive orders, Novo Nordisk says it remains committed to its DEI programmes.
(Reporting by Stine Jacobsen, editing by Terje Solsvik and Louise Heavens)
The article discusses the departure of Camilla Sylvest from Novo Nordisk and the subsequent executive changes.
Ludovic Helfgott will assume responsibility for product and portfolio strategy.
Yes, despite changes, Novo Nordisk remains committed to its DEI programmes.
Explore more articles in the Headlines category
